WASHINGTON & SARATOGA, Calif.--(BUSINESS WIRE)--

The Myelin Repair Foundation (MRF) today announced the support of the Ballenger Trust to accelerate the development of myelin repair therapeutics for multiple sclerosis (MS). The $700,000 gift will provide support for the MRF biomarker project, myelin repair research in human brain tissue and a repurposing opportunity. With the Ballenger Trusts support, these critical projects will accelerate the Myelin Repair Foundations research to develop a myelin repair therapeutic for multiple sclerosis.

The trustee of the Ballenger Trust, Chris Ballenger, selected the Myelin Repair Foundation to honor his fathers wish to accelerate new treatments for multiple sclerosis. Chris Ballengers sister Jacqueline passed away in 2009 from complications of MS. The MRF biomarker, human cell myelin repair assay and drug repositioning projects were selected for support by the Ballenger Trust to ensure promising myelin repair therapeutics enter clinical trials and benefit patients with MS.

The Myelin Repair Foundations myelin research for MS brings hope to patients with the disease, said Chris Ballenger, trustee of the Ballenger Trust. It was important for my father, John Ballenger to leave a long-lasting legacy to advance new treatments for those suffering from multiple sclerosis. With the Myelin Repair Foundations pioneering work in advancing myelin research into a drug for patients, I believe its our best chance to making my fathers dreams a reality.

We applaud the forward-thinking perspective of the Ballenger Trust to support several of our programs to advance promising myelin research, said Scott Johnson, CEO, President and Founder of the Myelin Repair Foundation. With their critical support, we are committed to honoring the memories of both John and Jacqueline Ballenger by continuing our progress towards developing a myelin repair drug for MS by 2019.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) (http://www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. Its Accelerated Research Collaboration (ARC) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.

Go here to see the original:
Ballenger Trust Selects the Myelin Repair Foundation to Advance Myelin Repair Therapeutic Development for Multiple ...

Comments are closed.